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For many malignant and nonmalignant hemato-
logic conditions, the only effective therapy is alloge-
neic hematopoietic cell transplantation (HCT). In
these settings, the consulting transplant physician of-
ten has the luxury of focusing on the reasons why
HCT is necessary and the risks of HCT. However, it
is common to encounter clinical settings in which
the decision as to whether to pursue transplant is less
straightforward. The advent of tyrosine kinase inhibi-
tors, such as imatinib, and its successors, changed the
decision process for patients with chronic myeloid leu-
kemia (CML), eventually leading to a dramatic drop in
HCT for CML. In the case of CML, relatively large
numbers of patients allowed for standard practice to
be guided by outcomes evidence. However, for more
rare diseases, the decision process remains difficult.
In this paper, the nontransplant and transplant treat-
ment options will be discussed for 3 less common
conditions: paroxysmal nocturnal hemoglobinuria
(PNH), hypoplastic myelodysplastic syndrome/aplas-
tic anemia (hMDS/AA), and Kostmann’s syndrome
(severe congenital neutropenia).PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA (PNH)
The pathobiology of PNH is unique [1]. PIGA,
located at Xp22.1, encodes a glycosyl transferase that
is an obligate constituent of a complex biochemical
pathway that leads to synthesis of the glycosyl phos-
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PNH is an acquired clonal disorder in which progeny
of affected hematopoietic stem cells are deficient in all
GPI-anchored proteins (GPI-APs) as a consequence of
somatic mutation of PIGA. The primary clinical man-
ifestations of PNH are hemolytic anemia, bone mar-
row failure, and thrombophilia [3]. The hemolytic
anemia of PNH is a consequence of complement-
mediated intravascular hemolysis, and mutant PIGA
explains directly the hemolysis of PNH because the 2
membrane proteins (DAF, CD55 and MIRL, CD59)
that are primarily responsible for protecting erythro-
cytes against complement-mediated lysis are GPI-
anchored [1]. In contrast, the relationship between
mutant PIGA and the bone marrow failure and throm-
bophilia of PNH is largely speculative.
For the clinical manifestations of PNH to become
apparent, the PIGA mutant clone must expand, but
PIGA mutant stem cells appear to have no intrinsic
growth or survival advantage [4]. These observations
suggest that clonal expansion is driven by factors dis-
tinct from mutant PIGA [5]. The peripheral blood of
patients with PNH is amosaic of normal and abnormal
cells. Although PNH is a clonal disease, it is not a ma-
lignant disease, and (for reasons that are enigmatic) the
extent to which the PIGA-mutant clone expands varies
widely among patients [1]. As an example, in some
cases, .90% of the peripheral blood cells is derived
from the PIGA-mutant clone, whereas in others,
\10% of the circulating cells are GPI-AP deficient.
This unique feature (variability in the extent of mosa-
icism) is clinically relevant because patients with rela-
tively small PNH clones have minimal or no
symptoms and require no PNH-specific treatment,
whereas those with large clones are often debilitated
by the consequences of chronic complement-mediated
intravascular hemolysis and respond dramatically to
complement inhibitory therapy.
The complement-mediated intravascular hemoly-
sis of PNH can be inhibited by blocking formation
of the membrane attack complex (MAC), the cytolytic
component of the complement system. The MAC
consists of complement components C5b, C6, C7,
C8, and C9. Eculizumab (Soliris, Alexion Pharmaceu-
tics, Inc., Cheshire, CT) is a humanized monoclonal
Table 1. Hematopoietic Stem Cell Transplant for PNH
Indications for transplant
 Bone marrow failure—approach to management depends primarily on
the underlying marrow abnormality (eg, aplastic anemia) but the
treatment regimen must be sufficient to eradicate the PNH clone
 Major complications of PNH
o Refractory, transfusion-transfusion dependent hemolytic anemia*
o Recurrent, life-threatening thromboembolic complications†
Conditioning regimens and donors
 Ablative and reduced intensity conditioning regimens have been
successful
 For transplants involving syngeneic twins, an ablative regimen is
recommended§
 Matched unrelated donor transplants have been successful but
experience is limited
Outcomes
 There are no PNH-specific adverse events. Severe, acute GVHD
occurs in approximately 33% of patients and the incidence of chronic
GVHD is roughly 35%
 Overall survival for unselected PNH patients who undergo
transplantation using an HLA-matched sibling donor is in the range of
50% to 60%
PNH indicates paroxysmal nocturnal hemoglobinuria.
*Treatment with eculizumab controls the intravascular hemolysis of
PNH. Mild to moderate extravascular hemolytic anemia persists in
most patients with PNH treated with eculizumab, likely because of op-
sonization of erythrocytes by activation and degradation products of
complement C3.
†Eculizumab may ameliorate the thrombophilia of PNH.
§Absence of graft-versus-host effect may render nonablative approaches
inadequate.
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activation to C5b and thereby inhibiting MAC forma-
tion. In 2007, eculizumab was approved by both the
U.S. FDA and the EU Commission for treatment of
the hemolysis of PNH. Treatment with eculizumab
reduces transfusion requirements, ameliorates the ane-
mia of PNH, and markedly improves quality of life by
resolving the debilitating constitutional symptoms as-
sociated with chronic complement-mediated intravas-
cular hemolysis [6]. Following treatment, serum
lactate dehydrogenase (LDH) concentration (a surro-
gate marker for intravascular hemolysis) returns to
normal, but mild to moderate anemia and reticulocy-
tosis usually persist, likely the result of ongoing extra-
vascular hemolysis mediated by opsonization of PNH
erythrocytes by activated complement C3, as eculizu-
mab does not block the downstream effects of comple-
ment activation. Thromboembolic events are the
major cause of morbidity and mortality in PNH [3],
and eculizumab appears to ameliorate the thrombo-
philia of PNH, although the studies that support that
conclusion were flawed by suboptimal study design [7].
Eculizumab is expensive ($400,000/year), and it
has no effect either on the underlying stem cell abnor-
mality or on the associated bone marrow failure. Con-
sequently, treatment must continue indefinitely, and
leukopenia, thrombocytopenia, and reticulocytopenia,
if present, persist despite treatment with eculizumab.
Prior to the availability of eculizumab, the primary
indications for transplant were bone failure, recurrent,
life-threatening thrombosis, and uncontrollable he-
molysis [3] (Table 1). The latter process can be elimi-
nated by treatment with eculizumab, and the
thrombophilia of PNHmay also respond to inhibition
of intravascular hemolysis by eculizumab [7]. None-
theless, transplant is the only curative therapy for
PNH, and the availability of molecularly defined
matched unrelated donors, less toxic conditioning reg-
imens, reduction in transplant-related morbidity and
mortality (TRM), and improvements in posttransplant
supportive care make this option increasingly attrac-
tive. The decision to transplant is complex, however,
and requires an understanding of the unique pathobi-
ology of PNH.
For patients who are being transplanted for bone
marrow failure, the focus of management is on the eti-
ology of the bone marrow failure (Table 1). Using
high-resolution flow cytometry to identify GPI-AP
deficient cells, 50% to 60% of patients with acquired
AA [8] and 10% to 20% of patients with low-risk mye-
lodysplastic syndrome (MDS) [9] can be shown to have
PNH cells in the peripheral blood. For patients with
AA and a small PNH clone who undergo matched sib-
ling donor allotransplant, the conditioning regimen of
antithymocyte globulin (ATG) and cyclophosphamide
coupled with graft-versus-host (GVH) effects appear
sufficient to eradicate the PNH clone [3]. However,in the unusual situation in which the patient has a syn-
geneic twin, a more intense conditioning regimen is
required, as GVH does not contribute to clonal erad-
ication in this circumstance [10]. In the event that a pa-
tient with low-risk MDS requires allotransplant, the
conditioning regimen (marrow ablative or reduced in-
tensity) in combination with GVH effects are suffi-
cient to eradicate the PNH clone.
Patients with classic PNH have clinical signs and
symptoms of intravascular hemolysis but have no evi-
dence of another defined bone marrow abnormality.
A cellular marrow with erythroid hyperplasia and nor-
mal or near-normal morphology, but without nonran-
dom karyotypic abnormalities is consistent with classic
PNH [3]. Transplantation for classic PNH is aimed at
eradicating the PNH clone, and both marrow ablative
[11,12] and reduced intensity [13,14] conditioning reg-
imens appear to be effective, although experience with
the latter is more limited. Successful outcomes have
been reported usingmatched unrelated donors as wells
as matched sibling donors [13,15].
There are no PNH-specific adverse events associ-
ated with transplantation; severe, acute graft-versus-
host disease (aGVHD) occurs in more than a third of
the patients and the incidence of chronic GVHD
(cGVHD) is roughly 35%. Overall survival (OS) for
unselected PNH patients who undergo transplanta-
tion using an HLA-matched sibling donor is in the
range of 50% to 60% [3].
PNH can occur in the young (about 10% of pa-
tients are younger than 21 at the time of diagnosis)
74 Biol Blood Marrow Transplant 15:72-78, 2009C. J. Parker et al.[3]. A retrospective analysis of 26 cases, underscored
the many similarities between childhood and adult
PNH [16]. Signs and symptoms of hemolysis, bone
marrow failure, and thrombosis dominate the clinical
picture, although gross hemoglobinuria as a present-
ing symptom may be less common in young patients.
A generally good response to immunosuppressive
therapy was observed [16], but based on poor long-
term survival, HCT is the recommended treatment
for childhood PNH. A more recent study [17] con-
firmed the common presentation of bone marrow fail-
ure in 11 children with PNH, and reported that 5
patients eventually underwent HCT (3 matched unre-
lated donors and 2 matched family donors), of whom 4
were long-term survivors. Although eculizumab is cur-
rently not approved for PNH patients younger than 18
years old, approval will likely be sought once pharma-
codynamic and pharmacokinetic characteristics of the
drug are defined for the pediatric population. The
availability of eculizumab for pediatric PNH may be
particularly advantageous as a bridge prior to imple-
mentation of more definitive therapy.
hMDS/AA
AA is 1 of several bone marrow failure disorders
that present with a hypocellular bone marrow and pan-
cytopenia.Most cases of acquired AA are caused by im-
mune-mediated destruction of bone marrow stem/
progenitor cells and can be treated with either immu-
nosuppressive therapy or allogeneic HCT [18]. How-
ever, it is important to recognize that a hypocellular
bone marrow and pancytopenia may also result from
nonimmune-mediated causes including genetic dis-
eases (eg, Fanconi anemia, dyskeratosis congenita,
etc.) or hMDS. Distinguishing between these disor-
ders can be challenging, but is critical to determine
the most appropriate therapy.
MDS is a clonal hematopoietic stem cell disorder
that produces multilineage hematologic cytopenias.
It is associated with heterogeneous karyotypic abnor-
malities, often involving chromosomes 5, 7, or 8, but
many cases have normal cytogenetics. Ineffective he-
matopoiesis and usually a hypercellular bone marrow
are unifying features; however, roughly 10% to 15%
of MDS patients have a hypocellular bone marrow
(hMDS). Distinguishing hMDS fromAA is can be par-
ticularly challenging, especially in older patients, be-
cause marrow cellularity normally decreases with age
and because hMDS is rare in children.
Work-up for Pancytopenia
A complete blood count, leukocyte differential, re-
ticulocyte count, bonemarrow aspirate and biopsy, pe-
ripheral blood flow cytometry for PNH [19] and bone
marrow karyotyping, and FISH analysis should be
performed on all patients. Flow cytometric assays todetect PNH cells can be performed with either mono-
clonal antibodies or a fluorescein-conjugated proaero-
lysin variant known as FLAER [20]. Unlike
monoclonal antibodies that bind the protein portion
of a GPI anchored protein, FLAER binds to the glycan
portion of the GPI anchor and is highly sensitive and
specific for detecting PNH cells. Patients\40 years
of age should be screened for Fanconi anemia using
the clastogenic agents diepoxybutane or mitomycin
C that test for increased chromosomal breakage. Up
to 10% of patients with Fanconi anemia will have
a false negative chromosomal breakage analysis be-
cause of mosaicism. In these patients, fibroblasts
from a skin biopsy or buccal smear can be used to es-
tablish the diagnosis. A family history of blood dyscra-
sias, pulmonary fibrosis, or premature graying of hair,
should raise suspicion for an inherited disorder, even
when physical abnormalities are not present.
Distinguishing between AA and hMDS
A hypocellular bone marrow is required for the di-
agnosis of AA. Spicules from an aspirate may be sur-
prisingly cellular in some AA patients despite overall
marrow hypocellularity because patients will occasion-
ally have residual pockets of ongoing hematopoiesis.
Thus, a 1- to 2-cm core biopsy is essential for assessing
cellularity. Mild dyserythropoiesis is not uncommon
in AA, especially in cases with simultaneous small- to
moderate-sized PNH populations; however, the pres-
ence of a small percentage of myeloid blasts or dysplas-
tic features in the myeloid or megakaryocyte lineages
favors a diagnosis of hMDS (Table 2). The percentage
of CD341 cells in the bone marrow is often helpful
[21]. CD34 is expressed on hematopoietic progenitors
and is fundamental to the pathophysiology of both dis-
eases; in MDS clonal expansion emanates from
a CD341 stem cell, and in AA the CD341 stem cells
are the target of an autoimmune attack. Accordingly,
the percentage of CD341 cells is usually #0.3% in
AA, whereas the CD34 percentage is either normal
(0.5 to 1.0 %) or elevated in hMDS [21].
The Presence of PNH Cells in AA and MDS
As previously noted, small to moderate PNH
clones are found in up to 60% of patients with acquired
AA, demonstrating a pathophysiologic link between
these disorders [8]. Typically, \10% GPI-AP-
deficient granulocytes are detected in AA patients at
diagnosis, but occasional patients may have larger
clones [22]. DNA sequencing of the GPI-AP-deficient
cells from AA patients reveals clonal PIGA gene muta-
tions. Moreover, many of these patients exhibit expan-
sion of the PIGAmutant clone and progress to clinical
PNH.
GPI-AP-deficient cells have also been reported in
patients with MDS [23], but sequencing of the PIGA
Table 2. Bone Marrow Findings That Help to Discriminate
Aplastic Anemia from Myelodysplasia
Characteristic Myelodysplastic Syndromes Aplastic Anemia
Cellularity Usually increased or normal* Decreased
CD34 count Normal to increased Decreased
Erythropoiesis
Megaloblastosis Common Common
Dyserythropoiesis Common Sometimes
Ringed sideroblasts Common Never
Myelopoiesis
Increased blasts Common Never
Megakaryocytes
Dysplastic Common Never
PNH clone Rare Common
PHN indicates paroxysmal nocturnal hemoglobinuria.
*A hypocellular bone marrow is found in up to 15% of cases of myelodys-
plastic syndromes.
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many of these studies. MDS patients reported to
have small PNH populations tend to be classified as
refractory anemia and often have the following charac-
teristics: a hypocellular marrow, HLA-DR15 pos-
itivity, normal cytogenetics, moderate to severe
thrombocytopenia, and a high likelihood of response
to immunosuppressive therapy [23]. It is likely that
many of these patients have moderate AA rather than
MDS. Thus, regardless of what one ‘‘names’’ the dis-
ease (hMDS versus AA), the more important issue is
to determine whether or not the bone marrow failure
is immune mediated. Unfortunately, there is no single
test that is 100% reliable in distinguishing between AA
and hMDS; however, the characteristics in Table 2
may be helpful in deciding on themost appropriate ini-
tial therapy.
Definitive Treatment
The etiology of bonemarrow failure (hMDSversus
acquired AA) and the degree of cytopenias are critical
for determining the best treatment approach. Patients
who meet criteria for acquired severe AA should be
treated with immunosuppressive therapy or an alloge-
neic HCT, depending on the age of the patient and
the availability of a suitably matched sibling donor
[18]. Most centers recommend allogeneic HCT from
amatched sibling donor for children and young adults.
Immunosuppressive therapy with antithymocyte glob-
ulin and cyclosporine (ATG/CsA) [24] or high-dose
cyclophosphamide [25] is recommended for patients
who are not ideal candidates for HCT because of age,
comorbid conditions, or lack of an HLA-matched sib-
ling donor.HCToffers the highest chance to cure SAA
(80% to 90% in patients \25 years old); however,
drawbacks include lack of suitable donors for most pa-
tients and risk for graft-versus-host-disease (GVHD).
Immunosuppressive therapy produces 5-year survival
rates that are comparable to HCT, but drawbacks in-
clude the risk of relapse and secondary clonal disorders
such as MDS and PNH. HCT from unrelated or mis-matched donors is usually reserved for patients who fail
to respond to 1 or more courses of immunosuppressive
therapy; the best results occur in children with disease
duration of less than 1 year [26].
Patients with hMDS should be managed in a simi-
lar manner to patients with standard MDS. Increased
blasts, unfavorable cytogenetics, and severe cytopenias
are ominous findings and predict poor survival. These
patients should be considered for allogenic HCT from
a matched sibling or alternative donor depending on
age, performance status, and availability of a suitable
donor. For those without poor risk factors, immuno-
suppressive therapy, or best supportive care may be ap-
propriate.KOSTMANN’S SYNDROME
A familial autosomal recessive hematologic disor-
der presenting as severe neutropenia and early onset
of severe infections was first described in Sweden by
Rolf Kostmann in 1956, and became known as Kost-
mann’s syndrome [27]. Later, other forms of severe
congenital neutropenia with either sporadic occur-
rence or autosomal dominant inheritance [28] were
identified, and it has been proposed that Kostmann’s
syndrome be used to refer only to autosomal recessive
disease and severe congenital neutropenia (SCN) be
used to describe the entire disorder. Patients afflicted
with SCN are usually diagnosed in the first months
of life after work-up for severe bacterial infections, of-
ten in the neonatal period, and usually involving the
skin or mucosa. Work-up demonstrates absolute neu-
trophil counts consistently under 200/mL, and the di-
agnosis is confirmed by bone marrow examination
demonstrating arrest of myelopoiesis maturation at
the promyelocyte/myelocyte stage [29]. The clinical
phenotype is further characterized by continuous re-
current bacterial infections, severe painful apthous ul-
cers, and failure to thrive. The peripheral blood
commonly reveals mild anemia, mild thrombocytope-
nia, monocytosis, and eosinophilia in addition to the
profound neutropenia. Prior to the availability of gran-
ulocyte colony stimulating factor (G-CSF), most pa-
tients died within the first 2 years of life. At the
present time, the incidence of SCN is estimated to
be around 5 cases per million population [30].
Molecular Explanations
Although the majority of patients with SCN nor-
malize their neutrophil counts once treatment with
G-CSF is initiated, contrary to expectations, studies
demonstrated that G-CSF receptor expression and
function is normal in SCN patients [31]. Other studies
showed normal to increased levels of G-CSF in SCN
patients [27]. The discovery in 1999 that mutations
in neutrophil elastase (Ela2) were responsible for
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shortly thereafter by the demonstration that Ela2 mu-
tations were also common in SCN patients. Eventu-
ally, it was determined that Ela2 mutations are
responsible for the majority of sporadic or autosomal
dominant forms of SCN [32]. Recent studies revealed
that expression of mutant neutrophil elastase leads to
cytoplasmic protein accumulation and stress apoptosis
[31]. At the same time, Hax1 mutations were demon-
strated to be the primary explanation for the autosomal
recessive form of SCN. Hax1 is thought to help main-
tain mitochondrial membrane potential, the loss of
which leads to a pro-apoptotic state [33]. Current
thinking attributes the maturation arrest in the mar-
row to stress apoptosis and improved neutrophil
counts with G-CSF treatment to the antiapoptotic ef-
fects of G-CSF.Treatment with G-CSF
In 1993, Dale et al. [34] published their landmark
study demonstrating conclusively that G-CSF was an
effective therapy for increasing blood neutrophils in
patients with SCN and significantly reducing the inci-
dence of infections. The Severe Chronic Neutropenia
International Registry (SCNIR) was established in
1994 in part to monitor outcomes for patients with
SCN treated with life-long GCSF. As of 2004, the
SCNIR has enrolled 1163 patients, including 526
with SCN. From this unique database we have been
able to determine typical effective doses of G-CSF
and adverse effects seen with long-term G-CSF treat-
ment in SCN patients. More than 90% of SCN pa-
tients will respond to G-CSF, with a median daily
dose 7.3 mg/kg/day (range: 0.01-242 mg/kg) to achieve
an absolute neutrophil count (ANC) of 1000 to 1500/
mL. Most of the patients who do not respond to G-
CSF present with very low ANC and allogeneic trans-
plant (discussed below) is the only life-saving option
for these patients [30]. The most common adverse
events have been those typically seen with GCSF ad-
ministration (headache, bone pain, musculoskeletal
symptoms). Osteopenia has been recognized in ap-
proximately 28% of patients, half of whom show
some evidence of osteoporosis. However, fractures re-
main rare and the significance of this finding is unclear
[30]. More concerning has been the finding that even
patients who respond to G-CSF remain at risk for sep-
sis-related mortality at a rate of just under 1% per year
over 12 years of follow-up [35]. A statistically signifi-
cant association was found between higher daily doses
of G-CSF and death from sepsis; the risk was particu-
larly high in patients requiring G-CSF dosed at 8 mg/
kg/day or more and patients whose ANC value on
treatment was\2188/mL. The risk of death from sep-
sis was increased 5.6-fold in patients with both risk fac-
tors [35]. The most serious event seen in SCN patientshas been evolution to MDS or acute myeloid leukemia
(AML) as discussed next.
MDS/Leukemia
In the pre-G-CSF era, occasional case reports led
to the recognition that patients with SCN were at
increased risk for AML. The mechanisms that lead
to leukemia remain unclear, but several relevant obser-
vations have been made [31,36]:
1. MDS/AML transformation occurs in both autoso-
mal dominant and autosomal recessive forms of
SCN
2. MDS/AML transformation is associated with 1 or
more genetic abnormalities, such as monosomy 7,
trisomy 21, RAS mutations, or G-CSF receptor
mutations
3. G-CSF receptor gene mutations that associate with
MDS/AML transformation result in a truncated
form of the receptor that separates proliferation
from maturation
4. The genetic abnormalities often detected in de novo
AML, such as FLT3, KIT, or NPM1 have not been
seen in SCN patients transforming to AML.
Once MDS/AML has developed, the prognosis is
dismal, with mortality rates approaching 100%
(Figure 1). Although remissions can be achieved with
chemotherapy, the serious infectious complications
are common and adequate neutrophil recovery can only
be reliably achieved with reinstitution of G-CSF.
Survival is dependent on undergoing a successful al-
logeneic HCT. Therefore, there has been consider-
able interest in identifying patients at greatest risk
of developing MDS/AML. The time from detection
of a G-CSF receptor mutation and development of
leukemia is very variable, and some patients remain
leukemia-free for years following first detection of
a mutation, and in other patients the detection of
a G-CSF receptor mutation has been transient.
Thus, the detection of G-CSF receptor mutations
has not led to the widespread transplantation of all
affected patients. A more convincing scenario is the
strong correlation of MDS/leukemia transformation
in patients who are less responsive to G-CSF than
average. Patients who received a higher than the me-
dian dose of G-CSF $8 mg/kg/day, but achieved an
ANC under 2188/mL at 6 to 18 months from initia-
tion of G-CSF therapy were very high risk of devel-
oping MDS/AML; at 10 years, 40% had developed
MDS/AML. About one-third of SCN patients fall
into this very high-risk population, and transplant is
becoming the treatment of choice for this group [35].
Transplant Outcomes
Patients with SCNwho have undergone allogeneic
HCT because of poor response to G-CSF have had
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Figure 1. Survival from time of diagnosis of MDS or AML for patients
treated without HCT (n 5 11) and with HCT (n 5 31).
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who underwent HCT received bone marrow from
HLA-matched siblings, but the number of patients
undergoing transplantation from alternative donors
(haploidentical, unrelated adult donors, unrelated
cord blood transplants) is growing [37-40]. Approxi-
mately 90% of patients transplanted for reasons other
than malignant transformation survived free from
SCN. On the other hand, outcomes for transplanta-
tion for MDS/AML transformation have been less fa-
vorable. There were only 3 survivors from the first 18
HCT reported to the SCNIR.However, over time, the
timing of transplantation has moved earlier in the
course of illness, and outcomes appear better for pa-
tients transplanted with MDS or very early after diag-
nosis of AML, with 9 of 12 patients surviving at least 1
year after HCT ([40,41], and Levine, unpublished
data), although late deaths from cGVHD remained
problematic. As shown in Figure 1, unpublished
SCNIR data from 1991-2005 reveals a median survival
from MDS/AML diagnosis of 6 months in 11 patients
who received treatment other than allogeneic HCT.
The median survival from MDS/AML diagnosis
was 13 months in 31 patients whose treatment in-
cluded allogeneic transplant (unrelated donor 20, un-
related cord blood 2, sibling donor 5, haploidentical
1, unknown 3). Presently, it is recommended that pa-
tients undergo allogeneic HCT from the best avail-
able donor as soon as evidence of malignant
transformation is identified, including characteristic
cytogenetic abnormalities such as monosomy 7 as
the sole abnormality. If AML is diagnosed, HCT
should be performed as soon as possible, preferably
before intensive chemotherapy.What to do with patients responding to G-CSF?
Patients responding to G-CSF need to be closely
monitored with routine complete blood counts and
annual bone marrow examinations, including cytoge-netic studies. Although decisions need to be individu-
alized for each patient, those who require more than
8 mg/kg/day of G-CSF should, at the minimum, be
monitored more frequently and HCT should be
considered, especially if there is an HLA-identical sib-
ling available.ACKNOWLEDGMENTS
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